REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's
FDA Approves Rexulti for Treating Agitation Due to Alzheimer's
SLU Researcher Finds Help for Alzheimer's-Associated Agitation
REXULTI® (brexpiprazole) Agitation associated with dementia due
US FDA approves Rexulti as first drug for agitation in Alzheimer's
FDA rushes approval of dementia drug that quadruples risk of death
FDA Accepts sNDA for Rexulti for Alzheimer's Agitation
For Alzheimer's Agitation, Promising News from Rexulti
FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation
Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for
de
por adulto (o preço varia de acordo com o tamanho do grupo)
